Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
33 Wet Macular Degeneration Trials
Power is an online platform that helps thousands of Wet Macular Degeneration patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Ocular Diseases, Uncontrolled Hypertension, Others
Must Be Taking:Anti-VEGF Injections
1000 Participants Needed
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
660 Participants Needed
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
990 Participants Needed
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Cincinnati, OhioThis trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
540 Participants Needed
SUSVIMO for Age-Related Macular Degeneration
Blue Ash, OhioThis study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Glaucoma, Autoimmune Diseases, Cancer, Others
Must Be Taking:Anti-VEGF
188 Participants Needed
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.
The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Proliferative Diabetic Retinopathy, Others
Must Be Taking:Anti-VEGF
1118 Participants Needed
NG101 Gene Therapy for Age-Related Macular Degeneration
Cincinnati, OhioThis study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Glaucoma, Retinal Detachment, Others
Must Be Taking:Anti-VEGF Injections
18 Participants Needed
Axitinib Implant for Age-Related Macular Degeneration
Beachwood, OhioThis trial is testing a small device placed in the eye that releases medication for patients with a severe form of AMD. The medication helps stop abnormal blood vessel growth in the eye, potentially preventing further vision loss. This approach has significantly improved treatment for this condition in recent years.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
344 Participants Needed
4D-150 + EYLEA for Age-Related Macular Degeneration
Cleveland, OhioA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Glaucoma, Uncontrolled Blood Pressure, Others
400 Participants Needed
EYP-1901 vs Aflibercept for Age-Related Macular Degeneration
Lexington, KentuckyThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Subfoveal Fibrosis, Atrophy, Scarring, Others
Must Be Taking:Anti-VEGF Injections
400 Participants Needed
Gene Therapy (ADVM-022) for Age-Related Macular Degeneration
Morgantown, West VirginiaNeovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
69 Participants Needed
OCU-10-C-110 Injection for Age-Related Macular Degeneration
Carmel, IndianaMulti-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Cancer, Dementia, Others
Must Be Taking:Anti-VEGF
19 Participants Needed
CG-P5 Peptide for Age-Related Macular Degeneration
Carmel, IndianaThis will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Glaucoma, Others
Must Not Be Taking:Retina-toxic Drugs
45 Participants Needed
OPT-302 + Ranibizumab for Age-Related Macular Degeneration
Ann Arbor, MichiganA 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
990 Participants Needed
Iptacopan for Age-Related Macular Degeneration
Indianapolis, IndianaThis trial tests if Iptacopan capsules can prevent worsening of early or intermediate AMD in people who already have severe AMD in one eye. The goal is to see if the medication can protect eye cells and slow down vision loss.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Arrhythmias, Stroke, Myocardial Infarction, End Stage Kidney Disease, Malignancy, Others
146 Participants Needed
4D-150 for Age-Related Macular Degeneration
Carmel, IndianaPhase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uveitis, Photodynamic Therapy, Others
Must Be Taking:Anti-VEGF
215 Participants Needed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Monocular, Fibrosis, Atrophy, Others
675 Participants Needed
EYP-1901 for Age-Related Macular Degeneration
Carmel, IndianaThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Subfoveal Fibrosis, Atrophy, Scarring, Others
Must Be Taking:Anti-VEGF Injections
400 Participants Needed
KHK4951 for Age-Related Macular Degeneration
Royal Oak, MichiganThis trial is testing special eye drops called KHK4951 to help people with a vision problem known as nAMD. The drops aim to improve vision by addressing abnormal blood vessels in the eye.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Glaucoma, Retinal Detachment, Others
Must Not Be Taking:Corticosteroids, Anti-VEGF, Others
180 Participants Needed
Axitinib Implant for Age-Related Macular Degeneration
Erie, PennsylvaniaStudy to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Monocular, Scar, Fibrosis, Atrophy, Others
Must Be Taking:Aflibercept
825 Participants Needed
RBS-001 vs Eylea for Age-Related Macular Degeneration
Erie, PennsylvaniaThis clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
434 Participants Needed
AXT107 for Age-Related Macular Degeneration
Erie, PennsylvaniaThe goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are:
* Safety of the maximum tolerable dose of AXT107
* Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:50 - 99
Sex:All
15 Participants Needed
AR-14034 for Age-Related Macular Degeneration
Erie, PennsylvaniaThe primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Ocular Disease, Glaucoma, Hypertension, Others
Must Be Taking:Ocular Anti-VEGF
140 Participants Needed
Aflibercept for Age-Related Macular Degeneration
Erie, PennsylvaniaIn neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 1
Age:All
Sex:All
12 Participants Needed
EXG102-031 for Wet Age-Related Macular Degeneration
Erie, PennsylvaniaIn neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Glaucoma, Others
Must Be Taking:Anti-VEGF
12 Participants Needed
NT-101 Eye Drops for Age-Related Macular Degeneration
Erie, PennsylvaniaPhase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
30 Participants Needed
Episcleral Brachytherapy for Wet Age-Related Macular Degeneration
Oak Forest, IllinoisThis is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the follow-up period.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50+
Sex:All
11 Participants Needed
EYE201 for Eye Conditions
Hagerstown, MarylandEYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.
All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Blood Pressure, Others
92 Participants Needed
Bevacizumab Safety for Retinal Disease
Chambersburg, PennsylvaniaThe study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
120 Participants Needed
Faricimab for Age-Related Macular Degeneration
Lemont, IllinoisThis study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:50+
Sex:All
274 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Wet Macular Degeneration clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Wet Macular Degeneration clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Wet Macular Degeneration trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Wet Macular Degeneration is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Wet Macular Degeneration medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Wet Macular Degeneration clinical trials ?
Most recently, we added RBS-001 vs Eylea for Age-Related Macular Degeneration, NT-101 Eye Drops for Age-Related Macular Degeneration and Faricimab for Age-Related Macular Degeneration to the Power online platform.